Nizubaglustat clinical trials
Also written AZ-3102.
How each study uses nizubaglustat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the nizubaglustat studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
6 studies that test it; most in 2025 (3); 1 more planned to start later
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2025 | 3 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Azafaros B.V. (7)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test nizubaglustat.
Studies
Open first, then newest update. How each study uses nizubaglustat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Study to Evaluate the Efficacy and Safety of Nizubaglustat (AZ-3102) in Patients With Gaucher Disease Type 3 (GD3)Not yet recruitingPhase 2Azafaros B.V.NCT07715084Written as AZ-3102
- A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)RecruitingPhase 3Azafaros B.V.NCT07082725Written as Nizubaglustat
- A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 GangliosidosisRecruitingPhase 3Azafaros B.V.NCT07054515Written as AZ-3102
- Long-Term Safety and Tolerability of Nizubaglustat in Participants With Rare Lysosomal DisordersNot yet recruitingPhase 2/3Azafaros B.V.NCT07885917Written as AZ-3102
- A Study to Evaluate the Safety and Efficacy of Nizubaglustat (AZ-3102) in Patients With GM2 Gangliosidosis or Niemann-Pick Type C DiseaseActive, not recruitingPhase 2Azafaros B.V.NCT07399704Written as AZ-3102
- A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of GM1 Gangliosidosis or GM2 GangliosidosisActive, not recruitingPhase 3Azafaros B.V.NCT07082543Written as AZ-3102
- Phase 2 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZ-3102 in Patients With GM2 Gangliosidosis or Niemann-Pick Type C DiseaseCompletedPhase 2Azafaros B.V.NCT05758922Written as AZ-3102 (Dose 1)
What changed recently
From the registry's own updates since Oct 18, 2026.
Newly registered1
Codes
What other systems call nizubaglustat · ClinicalTrials.gg INT014549
- UNII (FDA) 2X6NHN9RRNNIZUBAGLUSTATConfirmed FDA, Wikidata
- Wikidata Q140641146nizubaglustatConfirmed FDA, Wikidata
- NCI Thesaurus C199079NizubaglustatOne source FDA
- DrugBank DB21603One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 2X6NHN9RRN | NIZUBAGLUSTAT | Confirmed FDA, Wikidata |
| Wikidata | Q140641146 | nizubaglustat | Confirmed FDA, Wikidata |
| NCI Thesaurus | C199079 | Nizubaglustat | One source FDA |
| DrugBank | DB21603 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.